128 related articles for article (PubMed ID: 3055161)
1. Is interferon with or without vinblastine the "treatment of choice" in metastatic renal cell carcinoma? The Norwegian Radium Hospital's experience 1983-1986.
Fosså SD
Semin Surg Oncol; 1988; 4(3):178-83. PubMed ID: 3055161
[TBL] [Abstract][Full Text] [Related]
2. Recombinant alpha-interferon and vinblastine in metastatic renal cell carcinoma: efficacy of low doses.
Cetto GL; Franceschi T; Turrina G; Chiarion-Sileni V; Capelli MC; Bellini A; Paccagnella A; Bassetto MA; Molino AM; de Sandre G
Semin Surg Oncol; 1988; 4(3):184-90. PubMed ID: 3055162
[TBL] [Abstract][Full Text] [Related]
3. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma.
Fosså SD; de Garis ST; Heier MS; Flokkmann A; Lien HH; Salveson A; Moe B
Cancer; 1986 Apr; 57(8 Suppl):1700-4. PubMed ID: 3948141
[TBL] [Abstract][Full Text] [Related]
4. [Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil].
May M; Helke C; Bock M; Hoschke B
Urologe A; 2004 Sep; 43(9):1111-9. PubMed ID: 15232686
[TBL] [Abstract][Full Text] [Related]
5. Vinblastine and interferon-alpha-2a regimen in the treatment of metastatic renal cell carcinoma.
Palmeri S; Gebbia V; Russo A; Gebbia N; Rausa L
Tumori; 1990 Feb; 76(1):64-5. PubMed ID: 2321276
[TBL] [Abstract][Full Text] [Related]
6. Recombinant interferon-alpha combined with prednisone in metastatic renal cell carcinoma. Reduced toxicity without reduction of the response rate--a phase II study.
Fosså SD; Gunderson R; Moe B
Cancer; 1990 Jun; 65(11):2451-4. PubMed ID: 2337859
[TBL] [Abstract][Full Text] [Related]
7. Prediction of objective response to recombinant interferon-alpha with or without vinblastine in metastatic renal cell carcinoma.
Fosså SD; Nesland JM; Melvik JE; Jacobsen AB; Moe B
Acta Oncol; 1990; 29(3):303-6. PubMed ID: 2363942
[TBL] [Abstract][Full Text] [Related]
8. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study.
Fosså SD; Martinelli G; Otto U; Schneider G; Wander H; Oberling F; Bauer HW; Achtnicht U; Holdener EE
Ann Oncol; 1992 Apr; 3(4):301-5. PubMed ID: 1390305
[TBL] [Abstract][Full Text] [Related]
9. Combined interferon and vinblastine treatment of advanced melanoma and renal cell cancer.
Kellokumpu-Lehtinen P; Nordman E
Cancer Detect Prev; 1988; 12(1-6):523-9. PubMed ID: 3180144
[TBL] [Abstract][Full Text] [Related]
10. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
11. Recombinant interferon-alpha with or without vinblastine in metastatic renal carcinoma. Results of a randomised phase II study.
Fosså SD; Raabe N; Moe B
Br J Urol; 1989 Nov; 64(5):468-71. PubMed ID: 2611615
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer.
Marincola FM; White DE; Wise AP; Rosenberg SA
J Clin Oncol; 1995 May; 13(5):1110-22. PubMed ID: 7738617
[TBL] [Abstract][Full Text] [Related]
13. Combined treatment with low-dose interferon plus vinblastine is associated with less toxicity than conventional interferon monotherapy in patients with metastatic renal cell carcinoma.
Tsavaris N; Skarlos D; Bacoyiannis C; Aravantinos G; Kosmas C; Retalis G; Panopoulos C; Vadiaka M; Dimitrakopoulos A; Kostantinidis K; Mitropoulos D; Bougas D; Pantazopoulos D; Kosmidis P
J Interferon Cytokine Res; 2000 Aug; 20(8):685-90. PubMed ID: 10954911
[TBL] [Abstract][Full Text] [Related]
14. Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation.
Figlin RA; deKernion JB; Mukamel E; Palleroni AV; Itri LM; Sarna GP
J Clin Oncol; 1988 Oct; 6(10):1604-10. PubMed ID: 3049952
[TBL] [Abstract][Full Text] [Related]
15. Limited efficacy of interferon-alpha and vinblastine as second line biochemotherapy regimen in patients with progressive metastatic renal cell carcinoma.
Lopez Hanninen E; Fenner M; Kirchner H; Deckert M; Duensing S; Menzel T; Poliwoda H; Atzpodien J
Cancer Biother; 1993; 8(4):301-6. PubMed ID: 7804371
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of prolonged use of interferon-alpha in metastatic kidney carcinoma: a phase II study.
Kankuri M; Pelliniemi TT; Pyrhönen S; Nikkanen V; Helenius H; Salminen E
Cancer; 2001 Aug; 92(4):761-7. PubMed ID: 11550145
[TBL] [Abstract][Full Text] [Related]
17. A combination of vinblastine and doxorubicin with interferon alpha.
Jekunen A; Pyrhönen S
Am J Clin Oncol; 1996 Aug; 19(4):384-5. PubMed ID: 8677910
[TBL] [Abstract][Full Text] [Related]
18. An outpatient phase II study of subcutaneous interleukin-2 and interferon-alpha-2b in combination with intravenous vinblastine in metastatic renal cell cancer.
Pectasides D; Varthalitis J; Kostopoulou M; Mylonakis A; Triantaphyllis D; Papadopoulou M; Dimitriadis M; Athanassiou A
Oncology; 1998; 55(1):10-5. PubMed ID: 9428369
[TBL] [Abstract][Full Text] [Related]
19. Our experience with interferon alpha: renal cell carcinoma.
Merimsky O; Chaitchik S
Mol Biother; 1992 Sep; 4(3):130-4. PubMed ID: 1445666
[TBL] [Abstract][Full Text] [Related]
20. Further experience with recombinant interferon alfa-2a with vinblastine in metastatic renal cell carcinoma: a progress report.
Fosså SD; De Garis ST
Int J Cancer Suppl; 1987; 1():36-40. PubMed ID: 3476476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
